Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Advertisement
- Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society (ATS) International Conference in Dallas